Dustin Little United States

29 March 2026

Time	Session

8:10 a.m. 9:10 a.m.	Industry Symposium 5 HiddoLambers Heerspink Moderator Netherlands NaokiKashihara Moderator kashinao@med.kawasaki-m.ac.jpJapan Clinical Impacts and Importance of Minimizing Drug Approval Delay NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan HCE (hierarchical composite end points) and eGFR slope, as potential solutions to delays in approval HiddoLambers Heerspink Speaker Netherlands Bridging Academia and Regulators in Kidney Drug Development: Insights from Japan MototsuguTanaka Speaker Japan Panel Discussion DustinLittle Moderator United States HiddoLambers Heerspink Speaker Netherlands MototsuguTanaka Speaker Japan NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan 301 - 302
3:50 p.m. 4:50 p.m.	Industry Digest: Insights into Latest Innovations from Scientific Leads Advancing the Next Wave of Therapies in Chronic Kidney Disease DustinLittle Speaker United States Effects of Finerenone on Biomarkers: Mechanistic Insights From Proteomic Analyses in Clinical Trials MarioBerger Speaker mario.berger@bayer.comGermany Future Directions in CRM Care: Advancing Research and Therapeutic Innovation AntonioGarreta Rufas Speaker Germany Innovative Strategies for Clinical Trial Design in IgAN LokeshShah Speaker United States Improving Outcomes in Complement-mediated Kidney Diseases Marianne Silkjær Nielsen Speaker Switzerland Advancing Mechanistic Trials through Industry–Academia Collaboration: Insights from the REMODEL Trial ManuelMayrdorfer Speaker Denmark Why? When? How? How to Maximize Patient Outcomes From the Start of Dialysis PeterRutherford Speaker Switzerland 301 - 302